Amir Shojaei, PharmD, PhD, to Join iVeena Board of Directors
SALT LAKE CITY--(BUSINESS WIRE)--iVeena Delivery Systems, Inc. (iVeena), a clinical stage biopharmaceutical company with developmental products in cornea and cataract, announces the appointment of Dr. Amir Shojaei to the iVeena Board of Directors. Dr. Shojaei was the Vice President and Therapeutic Area (TA) Head in Ophthalmology at Shire/Takeda. He oversaw all aspects of clinical stage ophthalmic pipeline assets. Most recently, Amir's team brought Xiidra® (lifitegrast) from development to U.S.